Awarded TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup) investment (₩500M) from Ministry of SMEs and Startups (Korean government) with matching fund ($150K) from Bluepoint Partners. The funding will enable AevisBio to further develop the drug development platform (TArgeted Proteolysis Inducer, TAPI) technologies for the treatment of Triple Negative Breast Cancers.